Please wait while we load the price list
HealthDay - Drugs for Restless Legs Syndrome Have Downsides
November 13th, 2008The drugs that are widely used to treat restless legs syndrome do provide relief, but they are burdened by side effects and a gradual loss of effectiveness that causes many sufferers to stop taking them, a new analysis finds.
“One of t…
Parkinson’s Drugs May Cause Sleep Attacks
November 7th, 2008 Aug. 29, 2005 - A group of drugs commonly used to treat Parkinson’s disease may cause sudden sleep attacks in about one in five people who take them, according to a new study.
Researchers found 22% of people with Parkinson’s disease treated with drugs t…
Business Wire - Adnexus Therapeutics Announces Appointment of Timothy J. Rink, MD, ScD to Its Board of Directors
November 1st, 2008WALTHAM, Mass. — Adnexus Therapeutics, Inc. today announced Timothy J. Rink, MD, ScD has joined the Adnexus Board of Directors. Dr. Rink also currently serves as chairman of the Strategy Panel of the Technology Transfer division of the Wellcome Trust th…
Business Wire - Depression in Parkinsons Disease Has both Psychological and Pathological Causes
October 30th, 2008 DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c41448) has announced the addition of the new Datamonitor report “Pipeline Insight: Parkinsons Disease And Restless Legs Syndrome - Reformulations Set To Drive Near-Term Growth” to their offering.
Despite affecting a large number of individuals, there are currently no treatments capable of curing either Parkinsons disease or Restless Legs Syndrome. Although available treatments are effective, numer…
PR Newswire - Generic Erosion of Market Leading Therapies Will Constrain Growth in the Parkinson’s Disease Drug Market Over the Next Decade
October 25th, 2008 Modest Market Growth Will be Driven by the Arrival of Once-Daily Formulations of Dopamine Agonists, According to a New Report from Decision Resources
WALTHAM, Mass., June 17 /PRNewswire/ — Decision Resources, one of the world’s leading research and advisory fi…
Business Wire - Research and Markets: The Parkinsons Disease Market Is Set To Continue To Grow Over The Next 7 Years, Reaching Over $2.37 Billion In 2013, A 39% Increase From…
October 20th, 2008 DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c72211) has announced the addition of “Pipeline and Commercial Insight: Parkinsons Disease - Market to grow as first round of lifecycle management strategies” succeed to their offering.
Introduction
The PD market is set to con…
Pharma Marketletter - Requip shows use for restless legs syndrome.
October 15th, 2008The results of two studies showing the potential utility of GlaxoSmithKline’s Requip (ropinirole) in the treatment of restless legs syndrome were presented at the Associated Professional Sleep Societies’ annual meeting in Chicago, USA. There are currently no medicine…
Investors Chronicle - magazine and web content - GSK faces approval delay.
October 13th, 2008One of GlaxoSmithKline’s blockbuster replacement drugs is having approval problems Richard Hemming
Related Results
GSK faces approval delay.
…
Market Wire - Skyepharma PLC Announces Regulatory Approval
October 12th, 2008
FDA APPROVES REQUIP XL(TM), THE FIRST AND ONLY ORAL ONCE-DAILY
NON-ERGOT DOPAMINE AGONIST FOR PARKINSON’S DISEASE
Extended-Release Formulation Improved Symptoms in Patients Not
Optimally Controlled with Levodopa and Reduced Patients’”Off” Time by
Nearly Two Hours Per Day
LONDON, UK, 16 June 2008 — SkyePharma PLC (LSE: SKP) today announces
that the United States Food and Drug Administration (FDA)…
PR Newswire - U.S. FDA Approves Requip® XL™, the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinson’s Disease
October 6th, 2008 Requip XL Improved Symptoms in Patients Not Optimally Controlled with Levodopa and Reduced Patients’ “Off” Time by Nearly Two Hours Per Day
RESEARCH TRIANGLE PARK, N.C., June 13 /PRNewswire-FirstCall/ — GlaxoSmithKline today announced the approval of Requip(R) XL(TM) (ropinirole extend…
